February 02, 2012 08:00 ET

Equity Research on Amgen Inc. and Biogen Idec Inc. - Biotech Industry Growing

NEW YORK, NY--(Marketwire - Feb 2, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Amgen Inc. (NASDAQ: AMGN) and Biogen Idec Inc. (NASDAQ: BIIB). Register with us today at to have free access to these research reports.

The biotechnology industry started 2012 on a positive note as a whole but is facing a few headwinds. Increased costs, greater competition and the need to get new products to market may slow growth for some companies. Get your free reports on Amgen Inc. and Biogen Idec Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Amgen Inc. and Biogen Idec Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

The biggest positive for the industry is that several companies are reporting increased sales and revenues. Amgen Inc. saw sales climb approximately 3% to just shy of $4 billion in the fourth quarter. Biogen Idec Inc. had yet to report its fourth quarter figures at the time this article was written but the company did grow revenues 11.4% in the third quarter. Biogen Idec Inc. report is accessible for free by registering today at

Merger and acquisition activity is also on the rise for the industry. Amgen recently agreed to buy Micromet for $1.16 billion. Prior to the acquisition, the two companies had a partnership aimed at discovering and developing antibodies against tumors. This acquisition now gives Amgen complete ownership of the program and along with Micromet's other products will help expand its pipeline of oncology treatments. Amgen Inc. report is accessible for free by registering today at

The two Biotechnology stocks research reports are available for free by signing up now on

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information